It was shown to modulate the SIRT1/PPARγ pathway (Kim et al., 2015) as well as the SIRT1/FoxO axis (Kim et al., 2015), and its anti-inflammatory effects have been tested in clinical trials on Frail Elderly Syndrome (NCT03675724 and NCT03430037), symptomatic knee osteoarthritis patients (NCT04210986), chronic kidney diseases and diabetes (NCT03325322). The gene discussed is SIRT1; the disease is chronic kidney disease.